Cardiovascular Disease in Patients With Chronic Myeloid Leukemia

IF 12.8 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Jacc: Cardiooncology Pub Date : 2025-10-01 DOI:10.1016/j.jaccao.2025.06.007

Nazanin Aghel MD, MSc , Jeffrey Howard Lipton MD, PhD

引用次数: 0

Abstract

Cardiovascular (CV) disease and risk factors are notably prevalent among patients with chronic myeloid leukemia (CML). The introduction of BCR::ABL1 tyrosine kinase inhibitors has significantly transformed the treatment paradigm for CML. However, it is imperative to recognize that these therapeutic agents may lead to CV side effects. For instance, dasatinib has been associated with the development of pulmonary arterial hypertension, while nilotinib and ponatinib have been linked to various vascular complications. To accurately evaluate the incidence of CV events associated with CML treatment, systematic documentation of these occurrences in future clinical trials is essential. This approach will facilitate a deeper understanding of the CV implications of tyrosine kinase inhibitor therapy in patients with CML.

查看原文本刊更多论文

慢性髓系白血病患者的心血管疾病：JACC：心脏肿瘤学最新进展综述。

心血管（CV）疾病及其危险因素在慢性髓性白血病（CML）患者中尤为普遍。BCR::ABL1酪氨酸激酶抑制剂的引入显著改变了CML的治疗模式。然而，必须认识到这些治疗药物可能导致CV副作用。例如，达沙替尼与肺动脉高压的发生有关，而尼洛替尼和波纳替尼与各种血管并发症有关。为了准确评估与CML治疗相关的CV事件的发生率，在未来的临床试验中系统地记录这些事件是必不可少的。这种方法将有助于更深入地了解酪氨酸激酶抑制剂治疗CML患者的CV含义。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Jacc: Cardiooncology Multiple-

CiteScore

12.50

自引率

6.30%

发文量

106

期刊介绍： JACC: CardioOncology is a specialized journal that belongs to the esteemed Journal of the American College of Cardiology (JACC) family. Its purpose is to enhance cardiovascular care for cancer patients by publishing high-quality, innovative scientific research and sharing evidence-based knowledge. The journal aims to revolutionize the field of cardio-oncology and actively involve and educate professionals in both cardiovascular and oncology fields. It covers a wide range of topics including pre-clinical, translational, and clinical research, as well as best practices in cardio-oncology. Key areas of focus include understanding disease mechanisms, utilizing in vitro and in vivo models, exploring novel and traditional therapeutics (across Phase I-IV trials), studying epidemiology, employing precision medicine, and investigating primary and secondary prevention. Amyloidosis, cardiovascular risk factors, heart failure, and vascular disease are some examples of the disease states that are of particular interest to the journal. However, it welcomes research on other relevant conditions as well.